FDA Novo Nordisk - Search News

Novo Nordisk Shares Fall

The Wall Street Journal on MSN · 19m

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight.

Investopedia on MSN · 20m

Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.The average weight loss among those taking the new drug was 15.

Reuters on MSN · 3h

Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks.

3d

Novo Nordisk (NVO) Warns of Drug Shortages if Tariffs Are Imposed

Novo Nordisk (NVO), the company behind popular diabetes and weight loss medications Ozempic and Wegovy, warned that President ...

5don MSN

Down 39%. Is Novo Nordisk Stock a Buy on the Dip?

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

SWI swissinfo.ch1h

Novo’s New Obesity Drug Disappoints Again, This Time in Diabetes

Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot ...

4d

Novo Nordisk to sell Wegovy for $499 a month to cash-paying US customers

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...

GlobalData on MSN6d

Novo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic deal

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results